��������

This week, the Food and Drug Administration an update ending emergency use authorization for sotrovimab, a monoclonal antibody. “Data included in the health care provider  show the authorized dose of sotrovimab is unlikely to be effective against the BA.2 sub-variant,” the update stated. The Department of Health and Human Services estimates the omicron BA.2 sub-variant of SARS-CoV-2 is currently responsible for more than 50% of U.S. COVID-19 cases. (FDA , 4/5/22)